News und Analysen

If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs

AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over

Pfizer (NYSE: PFE) is deeply unloved today. There are a couple of reasons for this that are important, but the big story revolves around the company's drug portfolio. With three drugs facing patent

Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according

On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest

New York City-based Summit Street Capital Management increased its stake in Core Natural Resources (NYSE:CNR) by 81,170 shares in the third quarter, adding approximately $10.4 million in position

New York City-based Summit Street Capital Management fully exited its position in Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), reducing holdings by 281,812 shares during the quarter and

After months of uncertainty, President Donald Trump announced that the U.S. government would permit Nvidia (NASDAQ: NVDA) to sell its H200 processors to China. Trump announced the decision in a post

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%

In today's video, I discuss recent updates affecting Intel (NASDAQ: INTC), Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other artificial intelligence (AI) stocks. To learn more,

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other artificial intelligence (AI) stocks. To learn more, check out the short video, consider

Nvidia (NASDAQ: NVDA) stock gained 2.3% in after-hours trading on Monday, following President Donald Trump's reportedly posting on Truth Social that the U.S. government will allow Nvidia to export

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly

For the last three years, one piece of hardware has continually earned credit for the rise of generative artificial intelligence (AI) applications: the semiconductor. Naturally, investors sought

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (NASDAQ:VERX) in the third quarter. Despite the expanded stake, the market value of the

New York City-based Newtyn Management reported a buy of nearly 1.6 million additional Indivior PLC shares, increasing its position by an estimated $62.8 million in the third quarter, according to a

With energy demand surging globally, nuclear power is one energy source that checks all of the boxes. That's because it provides reliable, carbon-free power, providing consistent baseload energy

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than

Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a

Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.

However, one stock that hasn't matched its sector's returns is Halozyme

Pharmaceutical stocks have been on fire this year. The iShares U.S. Pharmaceuticals ETF (NYSEMKT: IHE), which tracks 43 drugmakers, is up almost 29% year to date and 11% over the past month.

There